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ABSTRACT
Context Some Ajuga L. (Lamiaceae) species are traditionally used for the treatment of malaria, as
well as fever, which is a common symptom of many parasitic diseases.
Objective In the continuation of our studies on the identification of antiprotozoal secondary
metabolites of Turkish Lamiaceae species, we have investigated the aerial parts of Ajuga laxmannii.
Materials and methods The aerial parts of A. laxmannii were extracted with MeOH. The H2O
subextract was subjected to polyamide, C18-MPLC and SiO2 CCs to yield eight metabolites. The
structures of the isolates were elucidated by NMR spectroscopy and MS analyses. The extract,
subextracts as well as the isolates were tested for their in vitro antiprotozoal activities against
Plasmodium falciparum, Trypanasoma brucei rhodesiense, T. cruzi and Leishmania donovani at
concentrations of 90–0.123 mg/mL.
Results Two iridoid glycosides harpagide (1) and 8-O-acetylharpagide (2), three o-coumaric acid
derivatives cis-melilotoside (3), trans-melilotoside (4) and dihydromelilotoside (5), two phenyletha-
noid glycosides verbascoside (6) and galactosylmartynoside (7) and a flavone-C-glycoside,
isoorientin (8) were isolated. Many compounds showed moderate to good antiparasitic
activity, with isoorientin (8) displaying the most significant antimalarial potential (an IC50 value
of 9.7 mg/mL).
Discussion and conclusion This is the first report on the antiprotozoal evaluation of A. laxmannii
extracts and isolates. Furthermore, isoorientin and dihydromelilotoside are being reported for the
first time from the genus Ajuga.
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Introduction
The majority of vector-borne parasitic infectious dis-
eases, such as malaria, African or American trypano-
somiasis and leismaniasis are generally categorized as
neglected tropical diseases (NTDs) due to their low
priority in western world as well as lack of interest of
pharmaceutical companies. NTDs principally affect
more than one billion people in 149 countries in the
world’s poorest regions (Feasey et al. 2010; WHO 2015a).
Malaria is caused by the protozoan parasite Plasmodium,
with P. falciparum being the deadliest. It is estimated that
584 000 malaria deaths occurred in 2013 worldwide and
453 000 of these deaths were children under 5 years of
age (WHO 2014). Human African trypanosomiasis
(sleeping sickness) is caused by Trypanasoma brucei
rhodesiense, a parasite which enters the body through the
bites of tsetse flies. An estimated 70 million people are at
risk (Feasey et al. 2010). Chagas’ disease (American
trypanasomiasis) that is caused by Trypanasoma cruzi
affects around 18 million people in Latin America.
According to World Health Organization (WHO), 7–8
million individuals are infected worldwide (WHO
2015b). Visceral leishmaniasis, which is also known as
Kala-azar, is caused by Leishmania donovani (Marinho
et al. 2015). It is estimated that 200 000–400 000 new
cases occur worldwide each year (WHO 2015c).
Although there are some available chemotherapeutic
drugs for the treatment of these infectious parasitic
diseases, the occurrence of widespread drug-resistant
strains as well as the serious adverse effects of the
currently used drugs points out the necessity of new, safe
and effective antiprotozoal agents. The use of medicinal
plants as a promising source for the development of new
CONTACT Hasan Kirmizibekmez hasankbekmez@yahoo.com Department of Pharmacognosy, Faculty of Pharmacy, Yeditepe University, _Istanbul 34755,
Turkey; Deniz Tasdemir dtasdemir@geomar.de GEOMAR Helmholtz Centre for Ocean Research Kiel, Research Unit Marine Natural Products Chemistry,
Kiel, Germany
 2016 Informa UK Limited, trading as Taylor & Francis Group
natural antiprotozoal drugs has long been a wise
approach.
The genus Ajuga L. (Lamiaceae) comprises around 300
species worldwide. Some Ajuga species, such as A. remota,
is traditionally utilized as an herbal remedy for the
treatment of fever, infections, malaria as well as tubercu-
losis (Israili and Lyoussi 2009; Cocquyt et al. 2011).
Hypoglycaemic, anti-arthritic, antioxidant, antimicrobial,
anti-fungal and anti-inflammatory effects of Ajuga species
have also been reported in previous studies (Kariba 2001;
El-Hilaly and Lyoussi 2002; El-Hilaly et al. 2006; Kaithwas
et al. 2012; Singh et al. 2012; Ben Mansour et al. 2013;
Hsieh et al. 2014). The genus Ajuga is represented by 11
species in the flora of Turkey (Davis 1982). Some of these
species are consumed for the treatment of haemorrhoids
and as a wound-healing agent in Anatolian folk medicine
(Sezik et al. 1992; Yesilada et al. 1995). Previous
phytochemical studies on Ajuga species have shown the
presence of diterpenes, phytoecdysteroids, iridoids, sterol
glycosides, flavonoids and phenylethanoid glycosides as
the secondary metabolites of the genus (De la Torre et al.
1997; Takasaki et al. 1998; Akbay et al. 2002, 2003; Sadati
et al. 2012; Inomata et al. 2013). There is only one report
on A. laxmannii (L.) Bentham collected from Bulgaria
stating the isolation of a diterpene, a coumarin, a
phytoecdysteroid, two iridoid glycosides and an o-
coumaric acid derivative (Malakov et al. 1998).
In the continuation of our studies on the isolation and
structure elucidation of antiprotozoal metabolites from
the plants of the family Lamiaceae found in Turkish
flora, now we have selected A. laxmannii for the
identification of its antiprotozoal secondary metabolites.
Our rationale for the selection of this genus was based on
the use of some Ajuga species for the treatment of
malaria, as well as fever, which is a common symptom of
all parasitic diseases of interest herein. We were further
encouraged by the reports on the in vivo and in vitro
antiplasmodial effects of the water extracts of some
Ajuga species, e.g. A. remota which is traditionally used
against fever and infections in Kenya (Kuria et al. 2001;
Gitua et al. 2012). Herein we describe the isolation and
structure elucidation of eight glycosides from A.
laxmannii as well as their in vitro antiprotozoal activities.
To our knowledge, this is the first study revealing the in
vitro antiprotozoal potential of A. laxmannii and its
secondary metabolites.
Materials and methods
General
NMR spectra were recorded on a Bruker AVANCE
500MHz Bruker spectrometer (Bruker Corporation,
New Orleans, LA). MS analyses were performed on a
Micromass Q-TOF Ultima Global Tandem Mass
Spectrometer (Bruker Corporation, New Orleans, LA)
using various concentrations of ACN in water and 0.1%
formic acid. Kieselgel 60 (0.063–0.200mm; Merck,
Darmstadt, Germany) and polyamide (Fluka, Newport
News, VA) were used for column chromatography (CC).
Thin-layer chromatography (TLC) analyses were con-
ducted on precoated Kieselgel 60 F254 (Merck,
Darmstadt, Germany) plates. For medium-pressure
liquid chromatography (MPLC), CombiFlash
Companion (Teledyne Isco, Lincoln, NE) apparatus
equipped with RediSep columns (C18, 130 and 43 g;
Teledyne Isco, Lincoln, NE) was used.
Plant material
The aerial parts of A. laxmannii were collected from
Vize, K{rklareli, Turkey, in May 2008. The plant material
was identified by Prof. Dr. Galip Akaydin (Department
of Biology Education, Faculty of Education, University of
Hacettepe, Beytepe, Ankara, Turkey). A voucher speci-
men (Akaydin 11862) has been deposited at the
Herbarium of the Faculty of Education, Hacettepe
University, Ankara, Turkey.
Extraction and isolation
The air-dried and powdered aerial parts of A. laxmannii
(300 g) were extracted with methanol (MeOH) (2.0 L) by
macerating for 3 d at room temperature. The extract was
filtered through a filter paper and evaporated to dryness
under reduced pressure to give the crude MeOH extract
(AjuLaxCRMeOH; 48,1 g, yield: 16.0%). The MeOH
extract was then dispersed in 75mL of MeOH–H2O
(40:35) mixture and extracted with n-hexane (4 75mL)
in order to remove lipids and waxes. The aqueous MeOH
phase was concentrated under reduced pressure and 40mL
H2O was added before partitioning against CHCl3
(4 75mL). The H2O subextract (AjuLax–H2O; 30 g)
was applied on a polyamide (110 g) column eluting with
H2O (300mL) and a stepwise gradient of MeOH in H2O
(10–100% in steps of 10%, each 200mL) to yield 12
fractions (Fr A–L). Fraction D (610mg) was separated by
C18-MPLC (130 g, 5–70%MeOH in H2O) and afforded Fr.
D5, 3 (14mg) and D7. Compound 1 (8mg) was purified
from Fr. D5 (20mg) by SiO2 (4 g) column chromatography
[CC] eluting with mixtures of CHCl3–MeOH–H2O
(85:15:1, 80:20:2 and 70:30:3). Likewise, Fr. D7 (52mg)
yielded compounds 2 (7mg) and 5 (10mg) by CC over
SiO2 (9 g) and eluting with mobile systems of CHCl3–
MeOH–H2O mixtures (95:5:0.5, 85:15:1 and 80:20:2).
Fraction F (802mg) was applied to C18-medium pressure
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liquid chromatography (C18-MPLC, 130 g) and eluted with
MeOH/H2O mixtures (10–100%) to obtain F7 (78mg)
which was further chromatographed over silica gel CC
(14 g) eluting with CHCl3–MeOH–H2O mixtures (95:5,
90:10:1, 85:15:1, 80:20:1, 75:25:1, 70:30:3 and 61:32:7) to
afford 7 (7mg). Fraction H (230mg) was subjected to
C18-MPLC (43 g) eluting with MeOH/H2O mixtures
(10–100%) to obtain 4 (5mg) and Fr. H3 (59mg). The
latter was further purified by SiO2 (9 g) CC eluting with
CHCl3–MeOH–H2O mixtures (95:5:0.5, 90:10:1, 85:15:1,
80:20:2 and 75:25:1) to yield compound 6 (20mg).
Fraction J (900mg) was similarly chromatographed by
C18-MPLC (130 g) using MeOH/H2O mixtures (20 to
90%) as an eluent to yield compound 8 (513mg).
In vitro assay for Plasmodium falciparum
Activity against erythrocytic stages of P. falciparum was
determined by an in vitro modified [3H]-hypoxanthine
incorporation assay, using the chloroquine- and pyri-
methamine-resistant K1 strain. Briefly, parasite cultures
were incubated in RPMI 1640 medium with 5%
Albumax (without hypoxanthine). A series of drug
dilutions were applied in microtitre plates and incubated
for 48 h at 37 C in a reduced oxygen atmosphere. After
incubation, 0.5 mCi 3H-hypoxanthine was added to each
well. Cultures were incubated for a further 24 h before
they were harvested onto glass–fibre filters and washed
with distilled water. The radioactivity was counted using
a BetaplateTM liquid scintillation counter (Wallac,
Zurich, Switzerland). The results were recorded as
counts per minute (CPM) per well at each drug
concentration and expressed as percentage of the
untreated controls. IC50 values were calculated from
the sigmoidal inhibition curves using Microsoft Excel.
Chloroquine was used as a standard drug.
In vitro assay for Trypanosoma brucei
rhodesiense
Trypanosoma brucei rhodesiense STIB 900 strain which
was isolated in 1982 from a human patient in Tanzania
and after several mouse passages cloned and adapted to
axenic culture conditions was used in this assay.
Minimum essential medium (50mL) supplemented with
25mM HEPES, 1 g/L additional glucose, 1% MEM non-
essential amino acids (100), 0.2mM 2-mercaptoethanol,
1mM Na-pyruvate and 15% heat inactivated horse serum
was added to each well of a 96-well microtitre plate. Serial
drug dilutions of seven 3-fold dilution steps covering a
range from 90 to 0.123mg/mL were prepared. Then 104
blood stream forms of T. b. rhodesiense STIB 900 in 50mL
were added to each well and the plate was incubated at
37 C under a 5% CO2 atmosphere for 72h. Alamar Blue
(resazurin, 12.5mg in 100mL double-distilled water)
(10mL) was then added to each well and incubated for a
further 2–4 h. At the end of the assay, the plates were read
with a Spectramax Gemini XS microplate fluorometer
(Molecular Devices Cooperation, Sunnyvale, CA) using an
excitation wavelength of 536 nm and an emission wave-
length of 588nm. Data were analyzed using the micro-
plate reader software Softmax Pro (Molecular Devices
Cooperation, Sunnyvale, CA). Melarsoprol was used as
standard drug for the assay.
In vitro assay for Trypanosoma cruzi
Rat skeletal myoblasts (L-6 cells) were seeded in 96-well
microtitre plates (2000 cells/well) in 100mL RPMI 1640
medium with 10% FBS and 2mM L-glutamine for 24 h.
After that, the medium was removed and replaced by
100mL per well containing 5000 trypomastigote forms of
T. cruzi Tulahuen strain C2C4 containing the b-galacto-
sidase (Lac Z) gene. The medium was removed from the
wells after 48 h, and replaced by 100mL fresh medium
with or without a serial drug dilution of seven 3-fold
dilution steps covering a range from 90 to 0.123 mg/mL.
After 96 h of incubation, the plates were inspected under
an inverted microscope to assure growth of the controls
and sterility. Then the substrate CPRG/Non-idet (50mL)
was added to all wells. A colour reaction developed
within 2–6 h and could be read photometrically at
540 nm. Data were transferred into the graphic
program Softmax Pro (Molecular Devices Cooperation,
Sunnyvale, CA) and the IC50 values were calculated.
Benznidazole was used as standard drug in this assay.
In vitro assay for Leishmania donovani
Amastigotes of L. donovani (strain MHOM/ET/67/L82)
were grown in axenic culture at 37 C in the SM medium
at pH 5.4 supplemented with 10% heat-inactivated FBS
under an atmosphere of 5% CO2. Culture medium
(100mL) with 105 amastigotes from axenic culture with
or without a serial drug dilution was seeded in 96-well
microtitre plates. Serial drug was prepared covering a
range of dilutions from 90 to 0.123mg/mL. After 72 h of
incubation, the plates were inspected under an inverted
microscope to assure growth of the controls and sterile
conditions. Alamar Blue (10mL) was added to each well
and the plates were incubated for another 2 h. The plates
were then read with a Spectramax Gemini XS microplate
fluorometer (Molecular Devices Cooperation, Sunnyvale,
CA) using an excitation wavelength of 536 nm and an
emission wavelength of 588nm. Data were analysed using
the software Softmax Pro (Molecular Devices Cooperation,
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Sunnyvale, CA). A decrease of fluorescence (¼ inhibition)
was expressed as percentage of the fluorescence of control
cultures and plotted against the drug concentrations. From
the sigmoidal inhibition curves, the IC50 values were
calculated. Miltefosine was used as a reference drug.
In vitro assay for cytotoxicity on mammalian cells
Assays were performed in 96-well microtitre plates
(4 104 L6 cells/well), each well containing 100 ml of
RPMI 1640 medium supplemented with 1% L-glutamine
(200mM) and 10% FBS. L-6 cells are a primary cell line
derived from rat skeletal myoblasts. Serial drug dilutions
of seven 3-fold dilution steps covering a range from 90 to
0.123mg/mL were prepared. After 72 h of incubation, the
plates were inspected under an inverted microscope to
assure growth of the controls and sterile conditions.
Alamar Blue (10 mL) was then added to each well and the
plates incubated for another 2 h. Then the plates were
read with a Spectramax Gemini XS microplate fluorom-
eter (Molecular Devices Cooperation, Sunnyvale, CA)
using an excitation wavelength of 536 nm and an
emission wavelength of 588 nm. Data were analyzed
using the microplate reader software Softmax Pro
(Molecular Devices Cooperation, Sunnyvale, CA).
Podophyllotoxin was the positive control.
Results
The in vitro antiprotozoal activity assays and cytotoxicity
test against mammalian L6 cells were performed as
described by Kirmizibekmez et al. (2011). As shown in
Table 1, the crude MeOH extract (AjuLaxCRMeOH) of
the plant showed moderate antiprotozoal activity against
T. b. rhodesiense and L. donovani (IC50 values of 10.8
and 30.1 mg/mL, respectively) without cytotoxicity
towards mammalian L6 cells at the highest test
concentrations. After partition against n-hexane and
CHCl3, the water subextract (AjuLax–H2O) of the crude
extract was selected for in depth chemical studies, as the
water infusion of the Ajuga species are traditionally used
for antimalarial or fever-relieving effects (Kuria et al.
2001). The H2O subextract exerted trypanocidal activity
against T. b. rhodesiense and T. cruzi (IC50 values of 17.5
and 37.4 mg/mL, respectively), and was subjected to a
gravity-driven column chromatography on polyamide
material. Further chromatographic separations of the
polyamide fractions by a combination of RP-MPLC and
gravity-driven silica CC led to the isolation of eight
known secondary metabolites (1–8) (Figure 1).
The chemical structures of the compounds were
identified as harpagide (1), 8-O-acetylharpagide (2)
(Calis et al. 1992), cis-melilotoside (3), trans-melilotoside
(4) (Vasa¨nge et al. 1997), dihydromelilotoside (5)
(Ranarivalo et al. 1990) verbascoside (6) (Sticher and
Lahloub 1982), galactosylmartynoside (7) (Takasaki et al.
1998) and isoorientin (8) (Calis et al. 2006) by
comparison of their 1D and 2D NMR and MS data
with those published previously.
Table 1 displays the antiprotozoal activities of the
isolated compounds from A. laxmannii. Since some of the
isolates (1, 2 and 6) had been isolated and evaluated for
their in vitro antiprotozoal activity in our previous studies
using the same panel of parasitic protozoa and experi-
mental methods (Kirmizibekmez et al. 2004; Tasdemir
et al. 2008), they were not tested again to avoid
duplication, however, their activity results are included
in Table 1 to allow comparison. It has to be noted that
these compounds have shown quite remarkable potential,
against T. b. rhodesiense and L. donovani. The most
significant activity was exhibited by the iridoid glucoside
8-O-acetylharpagide (2) against L. donovani with an IC50
value of 2.0mg/mL. Their trypanocidal activity was lower
(IC50 values from 14.2 to 26.9mg/mL). The remaining
Table 1. In vitro antiprotozoal and cytotoxic activities of crude MeOH extract (AjuLaxCRMeOH),
subextracts (AjuLax–Hex, AjuLax–CHCl3 and AjuLax–H2O) and compounds 1–8 from Ajuga laxmannii
(IC50 in mg/mL).
Extract/compound T. b. rhodesiense T. cruzi L. donovani P. falciparum Cytotoxicity (L6 cells)
AjuLaxCRMeOH 10.8 490 30.1 450 490
AjuLax–Hex 8.4 88.7 7.8 7.5 65.4
AjuLax–CHCl3 12.1 35.9 7.4 3.2 36.9
AjuLax–H2O 17.5 37.4 490 450 9.01
Standard 0.003a 0.38b 0.201c 0.12d 0.008e
1f 21.0 490 2.0 450 490
2f 26.9 490 6.9 450 490
3 4100 78.2 4100 450 84.1
4 58.9 58.0 4100 48.7 63.6
5 4100 56.3 4100 450 76.2
6g 14.2 490 8.7 450 37.1
7 31.6 57.4 4100 450 61.0
8 52.8 57.2 4100 9.7 71.6
Reference drugs: aMelarsoprol, bBenznidazole, cMiltefosine,dChloroquine, ePhodophllotoxin. fThese results are from our
earlier studies (Tasdemir et al. 2008). gThese results are from our earlier studies (Kirmizibekmez et al. 2004).
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compounds, with the exception of 3 and 5, exerted
moderate activity against T. b. rhodesiense with IC50
values ranging from 31.6 to 58.9mg/mL (Table 1). All
compounds except for 1, 2 and 6 moderately arrested the
growth of American trypanosome T. cruzi with IC50
values ranging from 56.3 to 78.2mg/mL. Although the
water subextract was inactive against P. falciparum, two
compounds, trans-melilotoside (4) and isoorientin (8)
displayed antimalarial effect, with isoorientin (8) appear-
ing the most potent one (an IC50 value of 9.7mg/mL). This
is probably due to masking effect of other, more major
compounds found in the H2O subextract. Cytotoxicity
assay towards mammalian (rat) L6 cells revealed that
most of the compounds possess low cytotoxicity, at least
at their active concentrations.
Discussion
The genus Ajuga has been reported to contain iridoids,
phenylethanoid glycosides, flavonoids, anthocyanins and
o-coumaric acid derivatives (De la Torre et al. 1997;
Takasaki et al. 1998; Akbay et al. 2002, 2003; Sadati et al.
2012; Inomata et al. 2013). Among the isolated com-
pounds in this study, harpagide or its acetyl derivative
8-O-acetylharpagide were also reported from other
genera of Lamiaceae including Stachys (Calis et al.
1992), Lamium (Alipieva et al. 2003) and Galeopsis
(Venditti et al. 2013). Harpagide has also been reported
from the genus Scrophularia (Tasdemir et al. 2005).
Iridoids are accepted as significant chemotaxonomic
markers in dicotyledonous plants. Thus, the occurrence
of harpagide or its 8-O-acetyl derivative might imply a
chemotaxonomic proximity between the genus Ajuga
and the other aforementioned genera of Lamiaceae along
with the genus Scrophularia from the family
Scrophulariaceae. Among the isolates, cis- and trans-
mellitoside (3 and 4) have previously been reported from
only one Ajuga species, namely Ajuga chamaecistus ssp.
tomentella (Sadati et al. 2012). This is the second report
of the presence of mellitoside from a member of the
Ajuga genus. Flavone-C-glycosides are relatively rare
compounds when compared with their O-analogues.
They were previously reported to be present in few
genera of Lamiaceae such as Scutellaria, Stachy and
Ajuga. Regarding the flavonoids, the O-glycosides of
apigenin and luteolin account for the major flavonoidal
constituents of the genus Ajuga, while C-flavonoid
glycosides such as isovitexin and orientin were rarely
encountered (Israili and Lyoussi 2009; Singh et al. 2012).
It is noteworthy that isoorientin was found as one of the
major constituents of A. laxmannii in this study.
Isoorientin (8) and dihydromelilotoside (5) are being
reported for the first time from the genus Ajuga.
Although this is the second phytochemical study on A.
laxmannii, six of the isolates (3–8) are being reported for
the first time from the title plant. Moreover, the extracts
and isolates were evaluated for their in vitro antiproto-
zoal and cytotoxic potential for the first time. Of note,
although the water subextract had no leishmanicidal or
antiplasmodial activity at the highest test concentrations,
several compounds isolated from this extract showed
such activity. The activity is probably masked by the
inactive compounds (e.g. sugars) that occur in high
concentrations in this subextract.
In a previous study, commercially available trans-
m-coumaric acid, trans-o-coumaric acid and trans-
p-coumaric acids were examined against L. major, but
none of them were found to be active (Takahashi et al.
2004). In this study, on one hand, trans-melilotoside (4),
which is the o-glycosylated form of trans-o-coumaric
acid, was also inactive against L. donovani, but exhibited
almost equipotent trypanocidal and antiplasmodial
activities. On the other hand, cis-melilotoside (3) and
dihydromelilotoside (5) were only moderately active
against T. cruzi. This may imply that trans configuration
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Figure 1. Structures of the isolated compounds (1–8).
1812 I. ATAY ET AL.
may be necessary for activity against T. b. rhodesiense
and P. falciparum.
In our previous study, glucopyranosyl-(1!Gi-6)-
martynoside isolated from another Turkish Lamiaceae
plant, Phlomis brunneogaleata, was shown to be
active against L. donovani and T. b. rhodesiense
(Kirmizibekmez et al. 2004). In the current work, a
very structurally related compound, galactosylmartyno-
side (7), was found to be active against both forms of
Trypanosoma. To our knowledge, it is the first report of
the antitrypanosomal activity of galactosylmartynoside.
Isoorientin (8) has previously been reported as the
antimalarial component of Hymenocardia acida from
Phyllantaceae (Murakami et al. 2005). In the current
study, isoorientin is being reported as the most active
antimalarial principle of A. laxmannii, which is consist-
ent with the previous study. Furthermore, isoorientin
also displayed moderate activity against T. b. rhodesiense
and T. cruzi in our panel of assays.
Conclusion
In conclusion, this is the first report on the in vitro
antiprotozoal activity testing and antiprotozoal activity-
guided isolation of eight secondary metabolites from
Turkish A. laxmannii. The current study provides a
preliminary confirmation of the traditional use of Ajuga
species in the relief of the symptoms of parasitic diseases.
Among the tested metabolites, the flavone-C-glycoside,
isoorientin (8) may deserve further studies such as in
vivo antimalarial tests. Finally, this study also reveals the
chemotaxonomic potential of some of the metabolites for
the genus Ajuga within the family Lamiaceae.
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